Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

BioAtla (BCAB) EPS (Weighted Average and Diluted) (2021 - 2025)

BioAtla (BCAB) has 5 years of EPS (Weighted Average and Diluted) data on record, last reported at -$0.27 in Q3 2025.

  • For Q3 2025, EPS (Weighted Average and Diluted) fell 22.73% year-over-year to -$0.27; the TTM value through Sep 2025 reached -$1.15, up 32.35%, while the annual FY2024 figure was -$1.44, 44.19% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.27 in Q3 2025 per BCAB's latest filing, up from -$0.32 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at -$0.22 in Q3 2024 and bottomed at -$0.9 in Q2 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$0.55, with a median of -$0.61 recorded in 2022.
  • Peak YoY movement for EPS (Weighted Average and Diluted): surged 68.12% in 2024, then decreased 22.73% in 2025.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$0.68 in 2021, then increased by 6.92% to -$0.63 in 2022, then rose by 11.11% to -$0.56 in 2023, then soared by 46.43% to -$0.3 in 2024, then rose by 10.0% to -$0.27 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Weighted Average and Diluted) were -$0.27 in Q3 2025, -$0.32 in Q2 2025, and -$0.26 in Q1 2025.